Study Stopped
recruitment difficulties
Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors
iALTE
Sponsor study identifier
interventional
12
1 country
4
Study Start
September 15, 2018
Actual (reported)Primary Completion
May 11, 2022
Actual (reported)Study Completion
May 11, 2022
Actual (reported)Apparent Life-Threatening Events (ALTE) in infants often lead to severe neurological complications or to sudden death. In such situations, cardio-pediatricians and intensive care physicians have no specific diagnosis or treatment. In a recent translational research (INSERM-DHOS), our team has reported a myocardiac abnormality in a rabbit model of vagal hyperreactivity which is also present in the human hearts of infants deceased from sudden death, i.e. increased M2 muscarinic receptors (M2R) density associated with compensative increased enzymatic activity and overexpression of acetylcholine esterase (AchE). In a recent PHRC-I study (article in preparation), these abnormalities have also been observed in the blood of patients, infants as well as adults, exhibiting severe vagal syncopes. We observed, even more importantly, similar abnormalities in infants under 1 year of age with very severe idiopathic ALTE (iALTE) compared with normal subjects and with patients who presented ALTE with identified etiologies (JAMA Pediatric, 2016 May). The aim of this present study is to validate the overexpression of M2R as a marker of risk of iALTE in infant under 1 year.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 11, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 31, 2017
Actual (reported)September 12, 2017
Actual (reported)September 15, 2018
Actual (reported)May 11, 2022
Actual (reported)May 11, 2022
Actual (reported)Muscarinic M2 receptor mRNA expression in blood
Blood sample will be collected not later than 24 hours after the inclusion in the study and will be frozen until centralized analysis. A qRT-PCR will be performed for quantification of CHRM2 gene expression in blood (mRNA expression). Interim analysis with the 7-8 first samples per group together. Final analysis with all samples at the study completion.
At the admission in the hospital, within 24 hours after the inclusion in the study
Acetylcholinesterase mRNA expression in blood
At the admission in the hospital, within 24 hours after the inclusion in the study.
Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
Standard management of ALTE * Hospitalization in pediatric intensive care unit or pediatric emergencies * Etiologic research * Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Pediatric Intensive Care unit/Emergency unit - Besançon University Hospital
Besançon, 25030, France
Pediatric Intensive Care Unit - Brabois Hospital - Nancy University Hospital
Nancy, 54500, France
Pediatric unit - Maison Blanche Hospital - Reims University Hospital
Reims, 51092, France
Pediatric intensive care unit/ Pediatric unit- Strasbourg University Hospital - Hautepierre Hospital
Strasbourg, 67200, France
Charlie DE MELO, MD
Hôpitaux Universitaires de Strasbourg
12 participants (actual enrollment reported by the registry).
First Submitted
August 31, 2017
First Posted
September 12, 2017
Study Start
September 15, 2018
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
May 11, 2022
Actual (reported)Study Completion
May 11, 2022
Actual (reported)Last Updated
July 10, 2026
Record last verified: 2022-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: